{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-007824","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.657621+00:00","generated_at":"2026-06-25T23:47:07.821233+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alector Q1 rev $24.5M, net loss $44.6M; latozinemab shows 54% disease progression delay in FTD-C9orf72","bullets":["Collaboration revenue $24.5M (vs $4.1M YoY) from GSK agreement; net loss $44.6M ($0.54/share) improved from $52.2M loss.","Cash, cash equivalents, and marketable securities $868.6M; sufficient to fund operations into mid-2024.","INFRONT-2 Phase 2: latozinemab in FTD-C9orf72 showed ~54% annual delay in disease progression vs matched control.","AL101 Phase 1 enrollment completed; data expected H2 2022. AL044 Phase 1 to initiate H2 2022.","Gary Romano, M.D., Ph.D., joins as CMO on May 23, 2022; Marc Grasso, M.D., joined as CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-007824","json":"https://secwatch.observer/filing/0000950170-22-007824.json","markdown":"https://secwatch.observer/filing/0000950170-22-007824.md","text":"https://secwatch.observer/filing/0000950170-22-007824.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017022007824/0000950170-22-007824-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017022007824/alec-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:47:07.821233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}